Literature DB >> 22808990

The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis.

Jinsong Xiao1, Shuangyun Chen, Chunlian Zhang, Shang Chang.   

Abstract

OBJECTIVE: To evaluate of metformin effectiveness of ovulation induction treatment in polycystic ovary syndrome (PCOS) women.
METHODS: Eight databases and nine related journals were searched for randomized controlled trails (RCTs) on the comparison between metformin and clomiphene citrate used for PCOS women. Meta analysis was performed after quality assessment.
RESULTS: Ovulation rate in metformin group compared with clomiphene citrate group was lower with a significant difference [OR = 0.48 (0.26-0.87), p = 0.01]; no significant difference was found for pregnancy rate [OR = 0.94 (0.26-3.43)], miscarriage rate [OR = 0.63 (0.06-6.47)] between two groups. Compared with the combination of metformin and clomiphene citrate group, pregnancy rate in metformin group was significantly lower [Peto OR = 1.56 (1.16-2.08), p = 0.003], but there was no significant difference in the two groups about ovulation rate [OR = 1.52 (0.95-2.45)], miscarriage rate [Peto OR = 1.40 (0.79-2.48)].
CONCLUSIONS: Compared with clomiphene citrate, metformin used for ovulation induction treatment in PCOS women, can promote ovulation induction and pregnancy rate, the effect of the combination treatment is better than that of a single drug use.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22808990     DOI: 10.3109/09513590.2012.705368

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  8 in total

1.  Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.

Authors:  Dmitri Madera; Lynn Vitale-Cross; Daniel Martin; Abraham Schneider; Alfredo A Molinolo; Nitin Gangane; Thomas E Carey; Jonathan B McHugh; Christine M Komarck; Heather M Walline; William N William; Raja R Seethala; Robert L Ferris; J Silvio Gutkind
Journal:  Cancer Prev Res (Phila)       Date:  2015-02-13

2.  Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study.

Authors:  Tannaz Moin; Jinnan Li; O Kenrik Duru; Susan Ettner; Norman Turk; Abigail Keckhafer; Sam Ho; Carol M Mangione
Journal:  Ann Intern Med       Date:  2015-04-21       Impact factor: 25.391

Review 3.  Gastrointestinal hormones and polycystic ovary syndrome.

Authors:  Jing Ma; Tzu Chun Lin; Wei Liu
Journal:  Endocrine       Date:  2014-05-04       Impact factor: 3.633

Review 4.  Metformin in women with PCOS, cons.

Authors:  Marie L Misso; Helena J Teede
Journal:  Endocrine       Date:  2014-09-02       Impact factor: 3.633

5.  A cell-autonomous molecular cascade initiated by AMP-activated protein kinase represses steroidogenesis.

Authors:  Houssein S Abdou; Francis Bergeron; Jacques J Tremblay
Journal:  Mol Cell Biol       Date:  2014-09-15       Impact factor: 4.272

6.  Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study.

Authors:  Evelin M Elia; Ramiro Quintana; Carlos Carrere; María V Bazzano; Gastón Rey-Valzacchi; Dante A Paz; María C Pustovrh
Journal:  J Ovarian Res       Date:  2013-09-08       Impact factor: 4.234

Review 7.  Medical and Surgical Treatment of Reproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews.

Authors:  Moustafa A Gadalla; Robert J Norman; Chau T Tay; Danielle S Hiam; Angela Melder; Jyotsna Pundir; Shakila Thangaratinam; Helena J Teede; Ben W J Mol; Lisa J Moran
Journal:  Int J Fertil Steril       Date:  2019-11-11

Review 8.  Therapeutic Potentials of Low-Dose Tacrolimus for Aberrant Endometrial Features in Polycystic Ovary Syndrome.

Authors:  Ahmad J H Albaghdadi; Frederick W K Kan
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.